Latest Deals
With its AI software, Cleerly is aiming to create a new standard of care for coronary artery disease (CAD). Credit: Mer_Studio / Shutterstock
Cleerly raises $106m to advance AI imaging platform for heart disease
Cleerly has concluded a $106m Series C funding round to advance its AI-driven coronary artery disease (CAD) platform. The US-based company’s non-invasive AI-Quantitative Coronary CT (AI-QCT) technology analyses coronary computed tomography angiography (CCTA) images to measure atherosclerosis to aid clinicians in developing personalised treatment plans for patients.
Dexcom invests $75m in ŌURA to forge partnership
Diabetes care device developer DexCom and ŌURA, maker of the Oura smart ring, have announced a strategic partnership that aims to provide users with a more complete picture of overall health. Dexcom has invested $75m in the ŌURA ‘s Series D funding round. Following the investment, ŌURA is now valued at more than $5bn.
Arlington Capital acquires TEAM Technologies to bolster healthcare portfolio
Private equity (PE) company Arlington Capital has signed a deal to acquire US-based medical device manufacturer TEAM Technologies from Clearlake Capital for an undisclosed sum. TEAM Tech specialises in manufacturing and strategic supply chain solutions and provides end-to-end outsourced design and manufacturing services to medical device and pharmaceutical OEMs.
Nihon Kohden expands neurology portfolio with Ad-Tech Medical acquisition
Nihon Kohden has expanded its portfolio of neurology electrode devices by acquiring a 71.4% stake in NeuroAdvanced Corp., the parent company of Ad-Tech Medical Instrument Corporation. The Japanese company noted that acquisition “Nihon Kohden’s established expertise in electro encephalograph (EEG) systems with Ad-Tech’s specialised electrodes, strengthening the company’s ability to support comprehensive epilepsy care.”
